Last $2.40 USD
Change Today +0.04 / 1.69%
Volume 745.0K
CTIC On Other Exchanges
Symbol
Exchange
BrsaItaliana
NASDAQ CM
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

cti biopharma corp (CTIC) Snapshot

Open
$2.38
Previous Close
$2.36
Day High
$2.44
Day Low
$2.35
52 Week High
01/21/14 - $4.25
52 Week Low
12/30/13 - $1.83
Market Cap
423.6M
Average Volume 10 Days
1.5M
EPS TTM
$-0.36
Shares Outstanding
176.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CTI BIOPHARMA CORP (CTIC)

Related News

No related news articles were found.

cti biopharma corp (CTIC) Related Businessweek News

No Related Businessweek News Found

cti biopharma corp (CTIC) Details

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the treatment of ovarian cancer; in phase II clinical trials for the treatment of malignant brain cancer; and is in phase II clinical trials for the treatment of head and neck cancer. Additionally, it is developing Brostallicin, which is in phase II clinical trials for the treatment of triple-negative breast cancer. The company has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat in North, Central, and South America, or the licensed territory; and a development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA to develop and commercialize Pacritinib worldwide. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

111 Employees
Last Reported Date: 03/4/14
Founded in 1991

cti biopharma corp (CTIC) Top Compensated Officers

Principal Founder, Chief Executive Officer, P...
Total Annual Compensation: $1.3M
Co-Founder, Principal Financial Officer, Prin...
Total Annual Compensation: $553.5K
Co-Founder, Chief Compliance Officer, Interim...
Total Annual Compensation: $551.0K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $585.0K
Compensation as of Fiscal Year 2013.

cti biopharma corp (CTIC) Key Developments

CTI Biopharma Corp. Announces an Analysis of Kinase Inhibition by Pacritinib

CTI BioPharma Corp. announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 clinical development, demonstrated a unique kinome profile among agents in development for myelofibrosis and suggests potential therapeutic benefit across a spectrum of blood-related cancers. One of the findings observed in clinical trials to date is the lack of myelosuppression seen with other treatments. Pacritinib's potent inhibition of FLT3, c-fms, IRAK1 and c-kit, all critical targets in hematologic malignancies, highlights its potential therapeutic utility in other indications, such as AML, MDS, CMML and CLL. The in vitro profiling of pacritinib across a panel of kinases showed the inhibition of all members of the JAK/FLT pathways, with the exception of JAK1. The JAK/FLT pathways are frequently dysregulated in many types of cancers. Additionally, pacritinib was found to inhibit the kinases c-fms and IRAK1. Disruption in the c-fms and IRAK1 pathways have been indicated to be involved in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL). CTI believes the clinical efficacy and reduced myelosuppression seen in Phase 2 trials of pacritinib in patients with myelofibrosis is also likely attributable to this unique kinase inhibition profile.

CTI Biopharma Corp. Proposes Amendments to Its Articles of Incorporation

CTI BioPharma Corp. announced that it will propose amendments to the company's amended and restated articles of incorporation to increase the total number of authorized shares from 215,333,333 to 315,333,333 and to increase the total number of authorized shares of common stock from 215,000,000 to 315,000,000, at its EGM to be held on February 27, 2015.

CTI BioPharma Mulls Acquisitions

CTI BioPharma Corp. (NasdaqCM:CTIC) is seeking acquisitions. CTI BioPharma is planning to raise funds from offering and plans to use part of proceeds for acquisitions. CTI BioPharma said, "We will retain broad discretion over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless we indicate otherwise in the applicable prospectus supplement, we anticipate that any net proceeds will be used for general corporate purposes or for strategic acquisitions from time to time."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CTIC:US $2.40 USD +0.04

CTIC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cytokinetics Inc $6.14 USD +0.27
Evotec AG €3.65 EUR -0.042
Exelixis Inc $1.33 USD +0.04
Navidea Biopharmaceuticals Inc $1.79 USD -0.21
Progenics Pharmaceuticals Inc $7.24 USD +0.25
View Industry Companies
 

Industry Analysis

CTIC

Industry Average

Valuation CTIC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 18.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CTI BIOPHARMA CORP, please visit www.ctibiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.